The relative deficiency of T helper type 1 (Th1) and cytotoxic T lymphocyte (CTL) responses in early life is associated with an increased susceptibility to infections by intracellular microorganisms. This is likely to ref lect Newborns and young infants are at enhanced risk of severe infection by intracellular microorganisms such as viruses or certain bacteria for which clearance requires the induction of strong cellular immune responses. The immaturity of CD8 cytotoxic T cells, natural killer (NK) cells, and macrophages in early life has long been recognized. However, it was only recently observed that this impairment of cellular responses could derive from a preferential polarization of immature CD4
Newborns and young infants are at enhanced risk of severe infection by intracellular microorganisms such as viruses or certain bacteria for which clearance requires the induction of strong cellular immune responses. The immaturity of CD8 cytotoxic T cells, natural killer (NK) cells, and macrophages in early life has long been recognized. However, it was only recently observed that this impairment of cellular responses could derive from a preferential polarization of immature CD4 T cells toward a T helper type 2 (Th2) rather than a Th1 pattern upon early exposure to antigen (1) (2) (3) (4) (5) . Thus, in contrast to a number of vaccines that successfully induce Th2 responses both in adults and young mice, neonatal Th1 responses are not easily elicited with conventional vaccines capable of eliciting Th1 responses in adults. This immunological bias of early-life responses leads to the generation of antibodies of different isotypes (low IgG2a in presence of significant IgG1 antibodies) and to a low secretion of interferon-␥ (IFN-␥) by antigenspecific CD4 T cells, and is associated with an impaired induction of cytotoxic CD8 T cells. As a consequence, mechanisms responsible for the destruction of infected cells and for the intracellular clearance of microorganisms are significantly impaired. Importantly, this Th2 bias may persist later in life (1) in spite of the progressive maturation of the immune system. Persistence of hepatitis B or cytomegalovirus infections after neonatal exposure is a clinical condition that may reflect this phenomenon.
It was recently shown that immunization with plasmid DNA expression vectors can induce strong Th1 vaccine responses in adult animals (reviewed in ref. 6) . Would this approach result in the induction of Th1-like responses in newborn or young mice in situations when conventional vaccines failed to do so? This question was addressed using several models of early-life immunization. We investigated the immunogenicity in early life of DNA plasmids encoding two model vaccine antigens, the measles virus hemagglutinin (MV-HA) and the fragment C of tetanus toxin (TetC), which can induce antigen-specific Th1-like or mixed Th1͞Th2 responses in adult BALB͞c mice (7, 8) . We extended our observations to a plasmid encoding another paramyxoviral antigen, the Sendai virus nucleoprotein (SV-NP), injected in the C57BL͞6 mouse strain known to differ in its indigenous polarization of immune responses. Finally, we addressed the question of whether DNA vaccines can be used to induce Th1 responses in spite of early-lifetriggered Th2 responses.
MATERIALS AND METHODS
Mice. Specific pathogen-free adult BALB͞c and C57BL͞6 inbred mice were purchased from Iffa Credo and kept under specific pathogen-free conditions. Breeding cages were checked daily for new births, and the day of birth was recorded as the day the litter was found. Pups were kept with mothers until weaning at the age of 4 weeks.
Vaccines. The DNA-HA vaccine contains the membranebound MV-HA (9) encoding cDNA subcloned into the pV1J (10) plasmid (7) . The TetC plasmid contains the synthetic gene encoding fragment C of tetanus toxin (TT) subcloned into the pcDNA3 (Invitrogen, R & D Systems) plasmid (8) . The cloned SV-NP gene (11) Immunization Procedures. Mice were immunized by groups of six to eight in the neonatal period (Ͻ24 h), as young mice (1-2 weeks), or as adults (controls). DNA vaccines were administered i.m. in each quadricep (adults, 50 l) or into each limb (1 week, 25 l). Immunization at Ͻ 24 h of life was performed by two quadricipital injections (25 l) of a concentrate (2-fold) DNA solution. For early-life immunization, 29-gauge insulin needles were used, and control adult mice were immunized in parallel. TT, MV-Schwartz, and AL-VAC-HA were given i.p. unless otherwise indicated.
Quantification of Vaccine-Specific Antibodies. Mice were bled at regular intervals for the determination of vaccinespecific serum antibodies. Serum MV-HA and TT antibodies were measured by ELISA as described (1) using either antigencoated plates or on Ltk-HA transfected cells. Total Sendaispecific antibodies were measured with heat-inactivated, purified Sendai virus-coated plates. Incubation was performed with serial serum dilution starting at 1͞100. After washing, the relevant isotype-specific peroxidase-conjugated goat or rabbit anti-mouse antibody (Zymed) was added for 2 h at 37°C prior to washing, incubation with substrate, and reading. Results of MV-HA and TT antibodies were expressed by reference to serial dilution of a titrated serum pool from immunized adult mice. For determination of Sendai-specific antibodies, antibody titers were calculated as the reciprocal of the last serum dilution that gave an OD 405 above that of the mean ϩ5 SD of the preimmune sera. Antibody titers below the cutoff of the assay were being given an arbitrary titer of 1͞2 the cutoff to allow calculation of geometric mean antibody titers.
Interleukin (IL)-5 and IFN-␥ Determination in Supernatant of in Vitro Restimulated T Cells. Splenocytes (10 7 ) were harvested 4 weeks after primary immunization. They were incubated at 37°C with vaccine antigen (TT, 10 g͞ml; MVSchwarz strain, 2.5 ϫ 10 5 CCID 50 ͞ml) in DMEM͞10% FCS or medium alone (control wells), as described (1) . Cell supernatants were collected after 48 and 72 h, and IL-5 and IFN-␥ content was measured by capture ELISA as described (1, 14) . Values for IL-5 and IFN-␥ were expressed by reference to a standard curve constructed by assaying serial dilution of the respective mouse cytokines. Values below the cutoff of the assay were being given an arbitrary titer of 1͞2 the cutoff. Antigen-specific cytokine secretion was obtained by subtracting the cytokine content of the supernatant from splenocytes incubated with DMEM alone.
Generation of CTLs and Cytotoxicity Assay. Splenocytes were harvested 4 weeks after immunization. Identical number of splenocytes from DNA-HA-immune mice were pooled and cultured as bulk or under limiting dilution conditions as described (1) . For this assay, varying numbers of responding cells were dispensed into 96 round-bottomed microwells together with 5 ϫ 10 5 irradiated syngeneic stimulator spleen cells, MVHA544-552 CTL peptide (20 g͞ml) (15), DMEM͞ 10% FCS, and EL-4 supernatant as a source of IL-2 (30 units͞ml). Fresh medium containing IL-2 was added on day 7. Control bulk cultures were tested on day 7, by adding varying number of effector cells to 51 Cr-labeled, HA-transfected or control P815 target cells (5 ϫ 10 3 ) in DMEM͞10% FCS. After 5 h of incubation at 37°C, cell supernatants were harvested for determination of 51 Cr in a ␥ counter. The percentage of specific lysis was calculated as [(experimental c.p.m. Ϫ spontaneous c.p.m.)͞(total c.p.m. Ϫ spontaneous c.p.m.)] ϫ 100. Spontaneous release and total release were determined from target cells incubated with medium alone or after the addition of 100 l of 1 M HCl, respectively. Individual wells of limiting dilution analyses were tested at day 10 for CTL activity. 51 Cr-labeled P815-HA (H2 d ) target cells (5 ϫ 10 3 ) were added to each well for a 5-h incubation at 37°C. Spontaneous release and total release were determined from target cells incubated with medium alone or after the addition of 100 l of 1 M HCl, respectively. Cell supernatants were harvested for determination of 51 Cr in a ␥ counter. Wells with a 51 Cr-release content superior to the mean value ϩ5 SD of the radioactivity measured in the supernatant of target cells alone were counted as positive wells. CTL precursor (CTLp) frequencies, which represent the mean frequency for the immune mice whose cells were initially pooled, were determined by the intersection of the regression line of the frequency of negative wells with the cutoff frequency of 37%.
Splenocytes from SV-NP-immune mice were cocultured for 5 days with an equivalent number of irradiated (2,500 rad) syngeneic spleen cells infected with the TR-5 Sendai virus strain (16) at a multiplicity of infection of 2͞1. The cytotoxic activity of responding cells was determined using 51 Cr-labeled, Sendai virus-infected, or control EL-4 (H2 b ) cells. Sendaiinfected target cells were produced by adding TR-5 Sendai virus at a multiplicity of infection of 10͞1, and the entire cell suspension was incubated in the presence of chymotrypsin for a further 12-16 h before use. Uninfected cells were given the same treatment, with mock allantoic fluid replacing the Sendai virus-infected allantoic fluid. Cocultures were incubated at various effector-target cell ratios for 4-6 h at 37°C, and specific cytotoxicity was calculated relative to the level of 51 Cr release in medium alone.
Statistical Analysis. Significance analysis between results obtained from various groups of mice was performed by using the Mann-Whitney U test. Probability values Ͼ0.05 were considered insignificant.
RESULTS

Induction of Adult-Like CD4 Th1 or Mixed Th1͞Th2 Vaccine Responses by a Single Dose of DNA Vaccine in Early Life.
To evaluate capacity of vaccines to induce Th1 responses in early life, a single dose (100 g) of a DNA plasmid encoding MV-HA was first given i.m. to groups of either adult or 1-week-old BALB͞c mice. Similar levels of MV-HA-specific antibodies were reached in either age groups (Fig. 1A) . These antibodies were enhanced 10-fold by booster DNA immunization performed 6 weeks later (data not shown). Comparative analysis of the IgG1 and IgG2a subclass distribution of vaccine antibodies, selected as indirect markers of Th1͞Th2-type responses, demonstrated that a similar profile of preferential IgG2a compared with IgG1 HA-specific antibodies was induced by DNA immunization in both juvenile and adult mice. In contrast, as previously observed (1), immunization with measles virus induced similar IgG1 (5.1 log 10 ) but significantly lower IgG2a vaccine antibody titers after immunization at 1 week of age (2.3 log 10 ) than in adults (4.0 log 10 ). Both total IgG and, more specifically, IgG2a vaccine antibodies induced by a single immunization of control juvenile BALB͞c mice with a live recombinant canarypox vaccine expressing MV-HA (ALVAC-HA) were also significantly reduced compared with adult primed mice (Fig. 1B) .
Adult and young BALB͞c mice were then immunized with another plasmid (TetC DNA). An antibody profile equally distributed between IgG1 and IgG2a antibodies was induced by this DNA construct regardless of age at immunization ( Fig.  2A) . This again was in contrast to the lack of detection of IgG2a vaccine antibody titers (Ͻ2 log 10 ) observed 2 weeks after TT immunization of 1-week-old vs. adult mice (3.4 log 10 ).
To define whether induction of adult-like antibody responses could be induced in early life in another mouse strain, adult and young C57BL͞6 mice were immunized with a different DNA vector encoding SV-NP. A similar vaccine isotype antibody pattern including preferential IgG2a vaccine antibodies compared with IgG1 antibodies was induced in either age group (Fig. 2B) . Thus, the vaccine antibody isotype distribution of mice primed in early life was similar in all and IL-5 as markers for the Th1 and Th2 pattern of CD4 T cell phenotype, respectively. In accordance with the respective antibody profiles, a pattern of mixed IFN-␥ and IL-5 secretion was present in the supernatant of antigen-specific T cells from mice immunized with TetC DNA (Fig. 3A) , whereas IFN-␥ was preferentially produced by antigen-specific T cells from mice immunized with MV-HA DNA (Fig. 3B) . Importantly, cytokine production patterns were similar in mice immunized either as adults or at 1 week of age. In contrast, early-life immunization with TT induced a much higher IL-5 production (data not shown), whereas the use of live recombinant AL-VAC-HA induced lower IFN-␥ and a much higher IL-5 production by T cells from mice primed at 1 week of age as compared with adults (Fig. 3C) .
Thus, in contrast to conventional vaccines, a single early DNA immunization induced vaccine antibody responses, including significant IgG2a antibodies and IFN-␥ production characteristics of Th1 or mixed Th1͞Th2 responses, as efficiently in early life as in adult animals.
Induction of Vaccine-Specific Cytotoxic Responses by DNA Immunization in Newborns and Early Life. The capacity of DNA vaccines to induce vaccine-specific CTLs before the age of 3-4 weeks was evaluated next. When C57BL͞6 mice were immunized with a single dose of SV-NP DNA (100 g) either as adults or as young mice, a cytolytic activity similarly resulting in the specific killing of Sendai-infected EL-4 target cells was observed (Fig. 4A) . (Fig. 4B) . Control lysis of untransfected P815 cells remained Ͻ20% under all conditions tested. This successful induction of CTLs by MV-HA DNA compared with ALVAC-HA was not due to a preferential CTL induction through the i.m. compared with the i.p. immunization route: in adult mice immunized i.m. with ALVAC-HA, CTLp frequency was significantly lower ( f ϭ 1͞12,500) compared with i.p.-immunized animals ( f Ͼ 1͞3,000). To further determine whether DNA vaccines could induce CTL responses independently of the stage of immune maturation, a single dose of MV-HA DNA (100 g) was administered to newborn BALB͞c mice within their first 24 h of life. When assessed 4 weeks after immunization, the CTLp frequency of mice immunized immediately after birth was similar to the one observed after immunization at 1 week of age or as adults (Fig. 4B) . Vaccine antibody profile and IFN-␥ production by T cells of newborn primed mice were also similar to those seen in mice immunized later in life (data not shown). Thus, strong Th1 and CTL vaccine responses can be triggered by neonatal DNA immunization before 24 h of life, at a time classically considered as favoring the induction of tolerance rather than immunity.
Importance of Age at Priming for the Pattern of Adult Responses. DNA vaccines have been reported as capable to induce Th1 responses in adult mice previously primed with a Th2 polarizing agent (17) . We thus wondered whether they could similarly induce Th1 responses in mice exhibiting a Th2-biased vaccine response following early-life immunization with another antigen presentation system. One-week-old BALB͞c mice were thus primed with ALVAC-HA and boosted 3 weeks later with either ALVAC-HA or MV-HA DNA. Boosting with MV-HA DNA did not increase MV-HA IgG2a antibodies, which remained at a very low titer of 2.1 log 10 . Comparison of the cytokine production by antigenspecific T cells of mice from either groups revealed a similar pattern consisting of low levels INF-␥ in the presence of very high levels of IL-5 (Fig. 5 ). This significantly differed from the antibody and cytokine patterns induced by a single MV-HA DNA immunization given at any age (Figs. 1 A and 3B) . Finally, MV-HA DNA boosting of mice primed with ALVAC-HA at 1 week of age did not increase CTLp frequencies, which remained similar to the low frequencies observed after earlylife ALVAC-HA priming and boosting (data not shown).
Thus, early-life responses of BALB͞c mice to vaccines can be polarized toward the Th2 phenotype to such an extent that later exposure to a strong Th1-driving DNA vaccine could not circumvent the influence of neonatal priming.
DISCUSSION
This report provides preclinical evidence of the potential advantages of DNA vaccines for the induction of cellular vaccine responses in early life. It demonstrates that adult-like Th1 and CTL vaccine responses against various viral or bacterial antigens can be raised by DNA immunization at any stage of the immune maturation of young mice, even immediately after birth. However, it also stresses the fact that the Th2 polarization following neonatal exposure to conventional vaccines extends into adult age to such a degree that it cannot be reverted by Th1-driving DNA vaccines. Each of the three DNA vaccines tested proved capable of inducing adult-like vaccine responses in young mice. Vaccine antibody patterns and cytokine production indicated that immunized mice preferentially raised Th1 responses in response to MV-HA or SV-NP DNA and responded to TetC DNA with a mixed Th1͞Th2 response. Importantly, these vaccine responses to DNA immunization, which probably depend on the biochemical nature of the antigen itself, were not affected by age at immunization. This is in striking contrast to the Th2-biased early-life responses already observed with other antigen presentation systems (1) . Use in early life of alum-adjuvanted peptide͞protein vaccines [tetanus toxoid, whole measles virus, inactivated Sendai virus (data not shown)], of live attenuated measles virus (data not shown), or even of live recombinant canarypox ALVAC-HA vaccines generated limited IgG2a antibody responses and IFN-␥ production in contrast to a burst of antigen-driven IL-5 production. These observations occurred independently of the nature of the antigen or of the antigen presentation systems.
Defective induction of CD8 cytotoxic responses (CTLs) had previously been observed in mice immunized up to the age of 3-4 weeks (1). CTLp frequency in 1-week-old mice immunized with live recombinant ALVAC-HA remained below 1͞20,000 compared with Ͼ1͞3,000 in adult primed mice. This CTL deficiency could represent merely a consequence of the defective induction of CD4 Th1 responses. Alternatively, additional deficiencies of the lytic machinery could have been present in early life. Our observation that DNA vaccines that induce strong CD4 Th1 responses also successfully induce vaccine-specific CTLs in early life suggests that the Th2 polarization of early vaccine responses is the main obstacle to the early generation of cytotoxic effector cells. Thus, selective vaccine strategies inducing Th1 and CTL responses in adults could be expected to generate CTLs in early life if strong enough Th1 responses can be induced.
CD4 Th1 and CD8 vaccine responses were thus elicited against various antigens, by several DNA plasmids, at various stages of the early immune maturation of either BALB͞c or C57BL͞6 mice. These observations are in accordance with preliminary observations describing induction of adult-like antibody patterns (18) or of CTL responses (19, 20) after neonatal immunization with plasmids encoding rabies virus glycoprotein, influenza nucleoprotein, or a murine retroviral antigen.
In contrast, they do not support the hypothesis by Mor et al. (21) based on immunization with a malaria circumsporozoite protein (CSP)-encoding plasmid, that neonatal DNA immunization favors neonatal tolerance induction. An explanation would be that this CSP DNA construct, whose immunogenicity is clearly weaker and different from the native protein, encodes only a few epitopes cross-reacting with self-antigens. An alternative explanation, which we favor, is that its weak immunogenicity might not be sufficient for priming in early life. In either case, our observations demonstrate that the immunogenic potential of DNA vaccines is worth assessing in the many situations in which the induction of early life Th1 and͞or CD8 responses would be desirable.
The demonstration that neonatal and early-life Th1 responses can be induced by DNA vaccines provides new insight into the mechanisms possibly at the basis of the Th2 bias of neonatal responses. Steps considered instrumental in the induction of primary Th1͞Th2 immune responses and thus potentially involved in the polarization of early immune responses have been identified at the level of (i) antigenpresenting cell (APC) activation and IFN-␣͞IL-12 production (2, 22, 23) , (ii) NK cell activity and IFN-␥ secretion (24) , and (iii) T cell activation requirements (25) . It was also considered possible that the Th2 cytokine milieu prevailing during pregnancy at the materno-fetal interface (26) could extend its influence to a period of time after birth and thus contribute to the shaping of immune responses in newborn and juvenile mice. The generic property of nucleic acids to raise strong Th1 responses in adult animals has been recently linked to the presence in bacterial DNAs of specific, unmethylated CpG motives capable of rapidly enhancing transcription of IL-6, IFN-␣, IFN-␥, and IL-12 in antigen-presenting cells (27) (28) (29) . This APC activation was found to result in NK cell͞T cell activation. The demonstration of the capacity of DNA plasmids to induce Th1 neonatal responses indicates that DNAtriggered mechanisms should already function early in life. Thus, the essential basic defect underlying the Th2 polarization of early responses can be found within the initial steps of neonatal APC activation, rather than in the ''downstream pathway'' of neonatal NK cell͞T cell activation. This APC activation defect could involve (i) variation in antigen presentation by immature APC, (ii) impaired activation of IL-12͞ IFN-␣ by viral or bacterial agents, or (iii) impaired molecular responses to yet undefined ''danger'' signals required for full activation of APC (2) .
The role of antigen presentation by neonatal APC in the shaping of neonatal responses can be evaluated in our MV-HA immunization model. In spite of a similar Th1-driving immunogenicity in adult mice, a DNA vaccine and a live viral vaccine (ALVAC-HA) encoding the same MV-HA antigen completely differ in their capacity to induce Th1 and CTL responses in early life. It is therefore likely that two different activation patterns of neonatal͞juvenile dendritic cells are triggered by these two antigen-presenting systems. Injections of DNA plasmids and of live recombinant canarypox share common features such as direct introduction and immediate transcription and expression of the encoded antigen within the cell. They differ, however, in the type of antigen exposure they generate: canarypox vectors have been reported as resulting in a strong and transient production of antigen (30) , whereas DNA vaccines induce low but prolonged antigen synthesis (31) . The pattern of antigen exposure to the immune system, including antigen load and͞or persistence, could thus play a crucial role in the shaping of early-life responses. The role of the dose of antigen had been identified in two reports, demonstrating that lowering the dose of antigen [adult male splenic cells (2) or infectious murine leukemia virus (3)] was sufficient to prime neonatal mice for Th1 responses. However, dose reduction failed to induce Th1 responses in all our models of early immunization with ''conventional'' vaccine antigens (1). We had postulated this discrepancy to reflect differences between the antigenic stimulation following neonatal infection with a replicating pathogenic live retrovirus and immunization with subunits or replication-deficient live viral vaccines. The observations reported here suggest that induction of Th1 responses in early life could require a prolonged exposure to low doses of antigen, as is achieved either by the use of infectious agents with prolonged replication patterns (3) or by DNA vaccines. This could be linked to the recently described requirement for prolonged antigen exposure to maintain expression of the IL-12 receptor ␤2 chain and thus drive CD4 T cells along the Th1 differentiation pathway (32, 33) .
Whether impaired activation of IL-12͞IFN-␣ by viral or bacterial agents also plays a role in the bias of neonatal responses cannot be inferred from these studies and is currently being assessed. However, our observations imply that if specific ''danger'' activation signals are required for induction of early Th1 responses, they would be similarly induced by live replicating agents and DNA vaccines but not by other Th1-driving vaccines such as replication-deficient live vectors. In this period of early life associated with immune immaturity, the use of DNA vaccines rather than live replicating agents would represent an obvious advantage.
We had previously shown that the influence of early priming with conventional vaccines or even live recombinant vector tends to persist in adult life (1). This occurred even if a vaccine (1997) boost was given with a Th1-driving adjuvant (34) . In adult mice, Th1-driving DNA vaccines were found capable of circumventing the Th2 response induced by priming with antigen [␤-galactosidase (␤-gal)] in alum: a change to a mixed Th1͞ Th2 response was achieved by boosting with a ␤-gal-encoding plasmid (17) . We show here that this is not the general case for Th2-biased responses induced in early life. Neither the low IgG2a responses, the IL-5 burst, nor the weak CTL induction typical of early ALVAC-HA priming were modified by boosting with MV-HA DNA. Thus, memory cells induced by early immunization appear strongly committed toward the Th2 pattern, at least in the more Th2-prone BALB͞c strain. Their IL-4͞IL-5 cytokine production probably maintains its domination over that of IL-12 and thus limits the polarization of newly induced Th1 cells by either specific adjuvant formulations (34) or DNA vaccines. Whether this is also the case in mice strains with an indigenous bias toward Th1 responses remains to be evaluated. This observation of the prolonged influence of Th2-biased CD4 T cells triggered in early life implies that vaccine strategies capable of inducing early Th1 and CD8 cytotoxic responses might have to include administration of a Th1-driving vaccine prior to exposure to either wild-type agents or Th2-driving conventional vaccine antigens.
In conclusion, the capacity of DNA vaccine to circumvent the tendency to develop preferential Th2 patterns of responses in early life is a promising observation for the development of vaccines against diseases caused in early life by viruses (e.g., cytomegalovirus, respiratory syncytial virus, or herpes simplex virus) or by other intracellular microorganisms such as mycobacteria or leishmania. Appropriate preclinical safety͞efficacy assessment should thus be conducted in newborn and young animals at initial stages of vaccine development.
